[Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China].
Chinese Journal of Hematology（2023）
关键词
mantle b-cell lymphoma,rituximab,bendamustine,treatment,first-line,non-hodgkin,real-world
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要